Diabetes vaccine studies have been underway for several years but progress is slow in translating these results into successful treatments for humans. There are several different types of diabetes vaccines on the market today, but none are available for use by people with Type I or Type II diabetes. However, there is one diabetes vaccine that is being evaluated in the United States and that may become a potential treatment for people with Type I and/or II diabetes. The diabetes vaccine holds great promise for treating both juvenile and chronic blood sugar-related conditions. While the vaccine is currently being tested in healthy adults, it has shown promising results in animals with non-diabetic conditions such as liver disease and pancreatic cancer.
Diabetes has become one of the most prevalent chronic diseases across the globe. For instance, according to World Health Organization, around 422 million individuals across the globe, have diabetes. The majority of the diagnosed cases have been found in low and middle-income nations and recently 1.6 million deaths are directly linked to the diseases annually. Owing to all these factors, there has been significant demand in the global diabetes vaccine market. Moreover, patients who are diagnosed with type 1 diabetes require constant monitoring and may also need external insulin shots, which they have to take intramuscularly daily. This especially becomes tough for children, which is augmenting the growth of the global diabetes vaccine market.
Based on early clinical trials in non-diabetic animals, the diabetes vaccine combines a pharmaceutical drug called C-peptide, a protein complex attached to an enzyme called GABA (primary inhibitor of insulin), and an antioxidant called superoxide dismutase (SOD). To date, much of the diabetes vaccine development has been conducted on laboratory animals, with very limited human testing being performed. However, the cost of the diabetes vaccines is the main restraining factor hindering the growth of the global diabetes vaccine market.
The prevalence of diabetes in North America is very high, there is a constant demand in the global diabetes vaccine market. For instance, according to the U.S. Centers for Disease Control and Prevention, around 34.2 million U.S. residents have been diagnosed with diabetes in 2020 and around 88 million adults have pre-diabetes. Moreover, the awareness among individuals related to diabetes control and health is also fueling the existing demand of the diabetes vaccine market. The favorable health policies and government support, the demand in the diabetes vaccine market in the Asia Pacific are also increasing constantly. Owing to all these factors, there have been some significant industrial developments in the global diabetes vaccine market. For instance, in 2018, Imcys announced the continuation of its clinical trials for developing new vaccines to treat type 1 diabetes.
In-depth Report on Global Diabetes Vaccine Market by Coherent Market Insights:
https://www.coherentmarketinsights.com/ongoing-insight/diabetes-vaccine-market-1367
No comments:
Post a Comment